Clinical Trial Software Market Revenue to Cross USD 3,684 Million by 2035 | Roots Analysis

Published: March 2024


According to a recently published report by Roots Analysis, the increasing prevalence of advanced analytical tools for real-time analysis of drug candidates and streamlining the drug development process has led to a surge in the demand for clinical trial software.

Clinical Trial Software Market Overview

The global clinical trial software market is anticipated to grow at a CAGR of 14% from 2023-2035, reaching USD 3,684 million by 2035.

The growth of the clinical trial software market is likely to be the result of the growing demand for advanced technologies for clinical studies in real-time.  A clinical trial is an important aspect of drug development to understand the therapeutic efficacy and safety of drugs for human consumption.  In order to get approval from regulatory authorities, pharmaceutical companies have to provide complete clinical trial reports with a higher accuracy level.  It is a well-known fact that manual conventional clinical trials are a time-consuming process and consume almost 50% of the time during drug development.  In this context, clinical trial software has gained significant attention owing to its ability for real-time analysis, data management, and tracking of the adverse impact of drugs.  To date, numerous clinical trial software / clinical trial management systems have been developed by the key players of the market, including EDC, eCOA / ePRO, and eConsent.  These tools enable real-time clinical studies and improve patient compliance for drug testing and analysis.  Owing to its significance, several clinical trial software market players are currently engaged in this field to develop innovative technologies to encourage successful outcomes of clinical trials and reduce the burden of pharmaceutical companies.  Owing to the increasing demand for automated clinical trial software, the market witnesses substantial growth during the forecast period.

The 141-page report contains a detailed Table of Contents on the "Clinical Trial Software Market," Type of Deployment, Type of Delivery, Features of Software, and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/clinical-trial-software-market.html

Market Drivers

Several market drivers that are propelling the clinical trial market include growing demand for advanced drug formulations to treat a wide range of diseases.  Further, the clinical trial market is also driven by the requirement for advanced data management software solutions that help to streamline clinical trial operations.  The pharmaceutical companies have to ensure compliance with regulatory standards to receive approval.  These clinical trial management solutions help to manage regulatory documentation, ensuring adherence to the guidelines and maintaining integrity.  Hence, the widespread adoption of efficient clinical trial software solutions has become the key driver of the market, which is anticipated to grow in the field in the upcoming years.

Market Restraints

Clinical trial software relies on data compliance from various resources; hence, data privacy is a major concern with technological solutions.  Furthermore, the cost associated with the installation of clinical trial software technologies may hinder the growth of the market during the forecast period.  The lack of standardization protocols may impede the seamless data sharing between different resources.

Growth Factors

Despite the market restraints, several growth factors are driving the clinical trial software market, including ongoing advancements in technologies to improve clinical trial outcomes.  The growing investment in research and development activities to develop innovative software solutions to improve clinical trial processes is the key driver of the market.  In addition, the growing adoption of automation tools in the clinical trial and drug development process is driving the clinical trial software market during the forecast period.

Clinical Trial Software Market Segments

Based on the features of the software, the clinical trial software market is segmented into EDC, eCOA/ePRO, and eConsent .

  • The eConsent software will dominate the clinical trial software market, capturing 79% of the overall share by 2035.
  • eCOA software will grow at a higher CAGR of 13.7% during the forecast period.

Based on the Regional Insights, the clinical trial software market is segmented into North America, Europe, and Asia Pacific. 

  • North America will dominate the clinical trial software market, capturing 39% of the overall revenue share by 2035.
  • In Asia-Pacific, the clinical trial software market will grow at a higher CAGR of 16.5% during the forecast period (2023-2035).

Key Companies Profiled

The Clinical Trial Software Market report also includes detailed profiles of key players (listed below) that offer advanced technological solutions for clinical trials:

  • Advarra
  • Arisglobal
  • AssistRx
  • Calyx
  • Clario
  • IBM
  • IQVIA
  • Medidata
  • Oracle
  • Signant Health
  • Veeva

You Can Download Free Sample PDF Copy of This Report At: 
https://www.rootsanalysis.com/reports/clinical-trial-software-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma/biotech market research.  Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.  All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject.  Apart from writing reports on identified areas, we provide bespoke research/consulting services dedicated to serving our clients in the best possible way.

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
Email: gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry